Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD, USA.
Proteomics Clin Appl. 2007 Aug;1(8):747-57. doi: 10.1002/prca.200700243. Epub 2007 Jul 13.
Probably no topic has generated more excitement in the world of proteomics than the search for biomarkers. This excitement has been generated by two realities: the constant need for better biomarkers that can be used for disease diagnosis and prognosis, and the recent developments in proteomic technologies that are capable of scanning the individual proteins within varying complex clinical samples. Ideally a biomarker would be assayable from a noninvasively collected sample, therefore, much of the focus in proteomics has been on the analysis of biofluids such as serum, plasma, urine, cerebrospinal fluid, lymph, etc. While the discovery of biomarkers has been elusive, there have been many advances made in the understanding of the proteome content of various biofluids, and in the technologies used for their analysis, that continues to point the research community toward new methods for achieving the ultimate goal of identifying novel disease-specific biomarkers. In this review, we will describe and discuss many of the proteomic approaches taken in an attempt to find novel biomarkers in serum, plasma, and lymph.
可能没有哪个主题能像生物标志物的研究那样在蛋白质组学领域引起如此多的关注。这种兴奋源于两个现实:对更好的生物标志物的持续需求,这些标志物可用于疾病的诊断和预后;以及蛋白质组学技术的最新发展,这些技术能够扫描不同复杂临床样本中的个体蛋白质。理想情况下,生物标志物可以从非侵入性采集的样本中进行检测,因此,蛋白质组学的大部分重点一直放在对生物体液(如血清、血浆、尿液、脑脊液、淋巴液等)的分析上。虽然生物标志物的发现一直难以捉摸,但在理解各种生物体液的蛋白质组内容以及用于分析它们的技术方面已经取得了许多进展,这些进展继续引导研究人员采用新的方法来实现识别新型疾病特异性生物标志物的最终目标。在这篇综述中,我们将描述和讨论许多蛋白质组学方法,这些方法试图在血清、血浆和淋巴中找到新的生物标志物。